Profilo
Gallia G.
Levy is currently the Chief Medical & Strategy Officer at Spark Therapeutics, Inc. Prior to this, she worked as an Associate Group Medical Director at Genentech, Inc. and as an Associate Group Medical Director-Hematology at Roche Holding AG.
Posizioni attive di Gallia Levy
Società | Posizione | Inizio |
---|---|---|
SPARK THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Gallia Levy
Società | Posizione | Fine |
---|---|---|
ROCHE HOLDING AG | Corporate Officer/Principal | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Direttore Tecnico/Scientifico/R&S | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ROCHE HOLDING AG | Health Technology |
Aziende private | 2 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
- Borsa valori
- Insiders
- Gallia Levy